share_log

BioVie | 424B5: Prospectus

BioVie | 424B5: Prospectus

BioVie | 424B5：募資說明書
美股SEC公告 ·  2024/10/23 04:04

Moomoo AI 已提取核心訊息

BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies for liver disease and neurological disorders, has announced the offering of 4,443,000 shares of its Class A common stock. The shares are being offered at a price of $1.50 per share, pursuant to a prospectus supplement and the accompanying base prospectus. Concurrently, BioVie is also offering warrants to purchase up to 4,443,000 shares of its common stock in a private placement. Each warrant has an exercise price of $1.37 per share, exercisable six months after issuance, with a term of five years from the initial exercise date. The offering is being facilitated by ThinkEquity LLC, acting as the exclusive placement agent. The placement agent is not purchasing or selling any securities but has agreed to use its reasonable best efforts to arrange for the sale of the securities offered. The offering is expected to close on or about October 22, 2024, subject to customary closing conditions. The date of the prospectus supplement is October 21, 2024.
BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies for liver disease and neurological disorders, has announced the offering of 4,443,000 shares of its Class A common stock. The shares are being offered at a price of $1.50 per share, pursuant to a prospectus supplement and the accompanying base prospectus. Concurrently, BioVie is also offering warrants to purchase up to 4,443,000 shares of its common stock in a private placement. Each warrant has an exercise price of $1.37 per share, exercisable six months after issuance, with a term of five years from the initial exercise date. The offering is being facilitated by ThinkEquity LLC, acting as the exclusive placement agent. The placement agent is not purchasing or selling any securities but has agreed to use its reasonable best efforts to arrange for the sale of the securities offered. The offering is expected to close on or about October 22, 2024, subject to customary closing conditions. The date of the prospectus supplement is October 21, 2024.
biovie公司是一家專注於開發治療肝臟疾病和神經系統疾病創新藥物療法的臨床階段公司，宣佈發行4,443,000股A類普通股。每股發行價爲$1.50，根據招股書補充和附屬基礎招股說明書發佈。與此同時，biovie還在定向增發中提供認購價值4,443,000股普通股的權證。每份權證的行權價爲每股$1.37，自發行後六個月可行使，行使期限爲自首次行權日期起五年。這一發行由ThinkEquity LLC完成，作爲獨家放置代理。放置代理不會購買或出售任何證券，但已同意盡最大努力安排出售所提供的證券。該發行預計將於2024年10月22日前後結束，視情況而定。招股書補充日期爲2024年10月21日。
biovie公司是一家專注於開發治療肝臟疾病和神經系統疾病創新藥物療法的臨床階段公司，宣佈發行4,443,000股A類普通股。每股發行價爲$1.50，根據招股書補充和附屬基礎招股說明書發佈。與此同時，biovie還在定向增發中提供認購價值4,443,000股普通股的權證。每份權證的行權價爲每股$1.37，自發行後六個月可行使，行使期限爲自首次行權日期起五年。這一發行由ThinkEquity LLC完成，作爲獨家放置代理。放置代理不會購買或出售任何證券，但已同意盡最大努力安排出售所提供的證券。該發行預計將於2024年10月22日前後結束，視情況而定。招股書補充日期爲2024年10月21日。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Nutriband
    NTRB
    -- 7.340
    Eterna Therapeutics
    ERNA
    -- 0.635
    Tonix Pharmaceuticals
    TNXP
    -- 0.3190
    ImmunoPrecise Antibodies
    IPA
    -- 0.645
    Sonnet BioTherapeutic
    SONN
    -- 2.0000
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啓，全球股市新風口在哪裏？
    ▪️加密貨幣政策能否利好crypto? ▪️關稅政策能否利好中概等海外資產？ ▪️在特朗普政策下，有哪些投資機會值得關注？ 展开
    離川普上臺只有7天了～
    熱門中概股
    追蹤最熱門的中概股實時資訊。